These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 35668668)
21. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695 [TBL] [Abstract][Full Text] [Related]
22. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma. Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942 [TBL] [Abstract][Full Text] [Related]
23. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990 [TBL] [Abstract][Full Text] [Related]
24. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of High-Specific-Activity Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194 [TBL] [Abstract][Full Text] [Related]
26. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Hartley A; Spooner D; Brunt AM Clin Oncol (R Coll Radiol); 2001; 13(5):361-6. PubMed ID: 11716230 [TBL] [Abstract][Full Text] [Related]
27. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103 [TBL] [Abstract][Full Text] [Related]
28. Predictive Factors of Early 18F-Fluorodeoxyglucose-Positron Emission Tomography Response to [131I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas. Takenaka J; Watanabe S; Abe T; Tsuchikawa T; Takeuchi S; Hirata K; Kimura R; Wakabayashi N; Shinohara N; Kudo K Neuroendocrinology; 2024; 114(9):816-826. PubMed ID: 37725921 [TBL] [Abstract][Full Text] [Related]
29. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196 [TBL] [Abstract][Full Text] [Related]
30. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Troncone L; Rufini V Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009 [TBL] [Abstract][Full Text] [Related]
32. Radiopharmaceutical treatment of pheochromocytomas. Sisson JC Ann N Y Acad Sci; 2002 Sep; 970():54-60. PubMed ID: 12381541 [TBL] [Abstract][Full Text] [Related]
33. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts. Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134 [TBL] [Abstract][Full Text] [Related]
34. Response to targeted radionuclide therapy with [ Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441 [TBL] [Abstract][Full Text] [Related]
35. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma. Zhang X; Wakabayashi H; Hiromasa T; Kayano D; Kinuya S Semin Nucl Med; 2023 Jul; 53(4):503-516. PubMed ID: 36641337 [TBL] [Abstract][Full Text] [Related]